Emergent BioSolutions' Q3 earnings report drives 20% surge in share price, reflecting market optimism. See why award a ...

Emergent BioSolutions raised its revenue guidance and dropped a going concern warning. Its CEO is billing this next chapter ...

At this time, I would like to welcome everyone to the Q3 2024 Emergent BioSolutions Inc. earnings conference call. All lines ...

The company is not selling any securities under this prospectus and will not receive any of the proceeds from the sale of securities by the ...

Q3 2024 Earnings Call Transcript November 6, 2024 Emergent BioSolutions Inc. beats earnings expectations. Reported EPS is ...

EPS: US$2.16 (up from US$5.09 loss in 3Q 2023). Revenue missed analyst estimates by 1.2%. Earnings per share (EPS) exceeded ...

Avidian Wealth Enterprises LLC cut its stake in shares of Emergent BioSolutions Inc. (NYSE:EBS – Free Report) by 20.4% during ...

Emergent BioSolutions expects a 2024 net loss of $203 million-$183 million, down from the previous loss range of $314 million ...

Emergent Biosolutions ( (EBS) ) has released its Q3 earnings. Here is a breakdown of the information Emergent Biosolutions presented to its ...

Shares of Emergent Biosolutions climbed after the company reported an increase in revenue and swung to a profit in the third quarter. The stock was up 28% to $11.81 in Thursday afternoon trading.

On Friday, Emergent Biosolutions Inc (EBS) stock saw a modest uptick, ending the day at $11.77 which represents a slight increase of $0.77 or 7.00% from the prior close of $11. The stock opened at $10 ...